Vaxcyte, Inc.
PCVX· Nasdaq
Released Nov 6, 2023, after the close
10-Q filed Nov 6, 2023, 37 days after period end · 0000950170-23-059395
| Metric | Q3 2023 | Q3 2022 | Q3 2021 | Q3 2020 |
|---|---|---|---|---|
| Net Income | -$92.66M | -$57.92M | -$26.62M | -$21.02M |
| EPS Diluted | -$0.91 | -$0.93 | -$0.51 | -$0.41 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vaxcyte, Inc. · CIK 1649094 · Engraved from SEC EDGAR